New drug combo tested to shrink oral cancer before surgery
NCT ID NCT02919683
Summary
This study is testing whether giving immunotherapy drugs before standard surgery can help shrink oral cavity cancer tumors. It involves about 30 adults with a specific type of head and neck cancer who are scheduled for surgery. Researchers want to see if the drugs, nivolumab alone or combined with ipilimumab, can reduce the cancer's size and potentially improve outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.